A5049694850- Cancer-related gene regulation
- Breast Cancer Treatment Studies
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Cancer Research and Treatments
- Advanced Breast Cancer Therapies
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Breast Implant and Reconstruction
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- AI in cancer detection
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Mechanisms and Therapy
- Salivary Gland Disorders and Functions
- TGF-β signaling in diseases
- Lung Cancer Treatments and Mutations
Keio University
2016-2025
Japan Cancer Society
2025
Keio University Hospital
2015-2024
Niigata University
2018
Niigata Cancer Center Hospital
2018
Toranomon Hospital
2018
Imperial College London
2014
Massachusetts General Hospital
2006-2011
Harvard University
2006-2011
University Hospital and Clinics
2011
The mechanisms underlying tumoral secretion of signaling molecules into the microenvironment, which modulates tumor cell fate, angiogenesis, invasion, and metastasis, are not well understood. Aberrant expression transcription factors, has been implicated in tumorigenesis several types cancers, may provide a mechanism that induces growth angiogenic factors tumors, leading to their local increase favoring progression. In this report, we demonstrate factor HOXB9 is overexpressed breast...
Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) is a 7-transmembrane reportedly expressed in stem cells of the intestinal crypts and hair follicles mice. Overexpression LGR5 observed some types cancer; however, there has been no specific assessment colorectal tumorigenesis. We performed quantitative RT-PCR for expression 37 representative cancer cell lines, showed that mRNA was frequently overexpressed colon lines. Moreover, higher lines derived from metastatic tumors...
Abstract Background To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, Clinical and Cancer Association, jointly published “Clinical practice guidance for next-generation sequencing cancer diagnosis treatment” 2017. Since new information on genomic medicine has emerged since 1st edition was released, including reimbursement NGS-based multiplex gene panel tests 2019, revision made. Methods A working group organized with 33 researchers from designated...
Abstract Triple-negative breast cancer (TNBC) chemoresistance hampers the ability to effectively treat patients. Identification of mechanisms driving can lead strategies improve treatment. Here, we revealed that protein arginine methyltransferase-1 (PRMT1) simultaneously methylates D-3-phosphoglycerate dehydrogenase (PHGDH), a critical enzyme in serine synthesis, and glycolytic enzymes PFKFB3 PKM2 TNBC cells. 13C metabolic flux analyses showed PRMT1-dependent methylation these three diverts...
Homeobox 9 (HOXB9), a nontransforming transcription factor overexpressed in breast cancer, alters tumor cell fate and promotes progression metastasis. Here we show that HOXB9 confers resistance to ionizing radiation by promoting DNA damage response. In nonirradiated cells, induces spontaneous damage, phosphorylated histone 2AX p53 binding protein 1 foci, increases baseline ataxia telangiectasia mutated (ATM) phosphorylation. Upon radiation, ATM is hyperactivated HOXB9-expressing cells during...
Abstract Background Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact PPIs co-administered with cyclin-dependent kinase 4 and 6 is controversial. We aimed to clarify whether concomitant use impacts palbociclib abemaciclib effectiveness in breast cancer treatment. Patients Methods This multicenter, retrospective, observational study, conducted across medical institutions Japan, consecutively included patients endocrine-resistant metastatic...
No consensus has been reached regarding the optimal chemotherapy for metastatic extramammary Paget's disease (EMPD), a rare cutaneous adenocarcinoma, because of lack solid evidence from prospective trials. However, immunohistochemical profile EMPD reportedly resembles that breast cancer, particularly in terms human epidermal growth factor receptor 2 (HER2) expression, suggesting HER2 is promising therapeutic target advanced HER2-positive EMPD.
The B-cell translocation gene-2 (BTG2) is present in the nuclei of epithelial cells many tissues, including mammary gland where its expression regulated during glandular proliferation and differentiation pregnancy. In immortalized breast cancer cells, BTG2 protein localized predominantly to nucleus cytoplasm, respectively. highly conserved domains (BTG boxes A, B, C) were required for regulating localization, suppression cyclin D1 growth inhibitory function BTG2. Expression analysis human...
The progression from preinvasive lesion to invasive carcinoma is a critical step contributing breast cancer lethality. We identified downregulation of milk fat globule-EGF factor 8 (MFG-E8) as contributor using microarray analysis laser capture microdissected (LCM) tissues. first MFG-E8 in lesions transgenic mammary tumor models, which were confirmed LCM-isolated human ductal carcinomas compared with patient-matched normal In situ analyses expression estrogen receptor (ER) positive cases its...
Epithelial-mesenchymal transition (EMT) is a multistep process in which cells acquire molecular alterations such as loss of cell-cell junctions and restructuring the cytoskeleton. There an increasing understanding that this may promote breast cancer progression through promotion invasive metastatic tumor growth. Recent observations imply there be cross-talk between EMT stem cell properties, leading to enhanced tumorigenicity capacity generate heterogeneous populations. Here, we review...
In Japan, the rising incidence of hereditary breast and ovarian cancer syndrome (HBOC) follows partial insurance coverage introduced in 2020. Compared with general population (~11% lifetime risk), individuals HBOC face a significantly higher risk (48%-76%), often presenting at younger ages. BRCA1 mutations are linked to triple-negative cancer, whereas BRCA2 typically result luminal-type disease. Key management strategies include surveillance prophylactic surgery. Annual magnetic resonance...
<title>Abstract</title> Background Sentinel lymph node biopsy (SLNB) has become a standard procedure for patients with breast cancer (BC) without clinically evident axillary metastasis. However, its role in cT3-4cN0 BC remains underexplored, leading to uncertainty regarding safety. Methods This retrospective, multicenter observational study included cT3-4cN0M0 who underwent radical surgery between 2006 and 2016. Patients were divided into an SLNB group, which those exclusively ALND after...
Abstract Assessing Erb-b2 receptor tyrosine kinase 2 ( ERBB2 ) amplification status in breast and gastric cancer is necessary for deciding the best therapeutic strategy. Immunohistochemistry (IHC) fluorescence situ hybridization (FISH) are currently used assessing protein levels gene copy number (CN), respectively. The use of next-generation sequencing (NGS) to measure CN approved by United States Federal Drug Administration as a companion diagnostic. However, less than 8 evaluated...
Disrupted imprinting is implicated in certain tumorigenesis. Since aberrant methylation has been described for a majority of microsatellite instability (MSI)-positive sporadic colorectal cancers, we have investigated alteration to the 55 cancers with or without MSI. Loss (LOI) IGF2 and PEG1/MEST was observed 42% 35% informative respectively. H19 expression not detected 24% cancers. SNRPN NDN retained monoallelic all examined. These findings indicate no simultaneous disruption imprinted...